High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8195-8203

  Huang, Shiu Feng ^a   Liu, Hui Ping ^a   Li, Ling Hui ^a   Ku, Yuan Chieh ^a   Fu, Yu Ning ^a   Tsai, Hsien Yu ^a   Chen, Ya Ting ^a   Lin, Yung Feng ^a   Chang, Wen Cheng ^a   Kuo, Han Pin ^a   Wu, Yi Cheng ^a   Chen, Yi Rong ^a   Tsai, Shih Feng ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG RESPONSE; ETHNOLOGY; EXON; FROZEN SECTION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; TAIWAN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, NUCLEIC ACID; TAIWAN;

EID: 19944426858     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1245     Document Type: Article

References (25)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
2. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
4. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15.
7. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-85.
8. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241-49.
9. Lai WW, Chen FF, Wu MH, et al. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 2001;72:1868-76.
10. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42.
11. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
13. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-30.
14. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
15. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
16. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients 'with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003;290:2149-58.
17. Tsai CM, Chiu CH, Chen YM, Perng RP. Gefitinib in patients with advanced non-small cell lung cancer: relationship between drug toxicity and tumor response. Thoracic Medicine 2003;18:S6:93.
18. Wu MF, Fahn HJ, Wu TC, et al. Experience of gefitinib (Iressa) for previously treated patients with advanced non-small cell lung cancer. Thoracic Medicine 2003;18:S6:203.
19. Chen KC, Chang GC, Yang TY. A comparison of gefitinib monotherapy and chemotherapy with cisplatin and gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A case control study. Thoracic Medicine 2003;18:S6:218.
20. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
21. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-30.
22. Bailey R, Kris M, Wolf M, et al. Gefitinib ('Iressa',ZD1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL I and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2004;41:S2:71.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
24. Paez JG, Jänne PA, Lee JC, et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash DC) 2004;304:1497-500.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst (Bethesda) 2000;92:205-16.